Presence of donor-encoded centromeric KIR B content increases the risk of infectious mortality in recipients of myeloablative, T-cell deplete, HLA-matched HCT to treat AML

Will P. Bultitude, Jennifer Schellekens, Richard M. Szydlo, Chloe Anthias, Sarah A. Cooley, Jeffrey S. Miller, Daniel J. Weisdorf, Bronwen E. Shaw, Chrissy h. Roberts, Christian A. Garcia-Sepulveda, Julia Lee, Rachel M. Pearce, Marie C. Wilson, Michael N. Potter, Jenny L. Byrne, Nigel H. Russell, Stephen MacKinnon, Adrian J. Bloor, Amit Patel, I. Grant McQuakerRam Malladi, Eleni Tholouli, Kim Orchard, Victoria T. Potter, J. Alejandro Madrigal, Neema P. Mayor, Steven G.E. Marsh

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

The reported influence of donor Killer-cell Immunoglobulin-like Receptor (KIR) genes on the outcomes of haematopoietic cell transplantation (HCT) are contradictory, in part due to diversity of disease, donor sources, era and conditioning regimens within and between different studies. Here, we describe the results of a retrospective clinical analysis establishing the effect of donor KIR motifs on the outcomes of 119 HLA-matched, unrelated donor HCT for adult acute myeloid leukaemia (AML) using myeloablative conditioning (MAC) in a predominantly T-cell deplete (TCD) cohort. We observed that HCT involving donors with at least one KIR B haplotype were more likely to result in non-relapse mortality (NRM) than HCT involving donors with two KIR A haplotypes (p = 0.019). Upon separation of KIR haplotypes into their centromeric (Cen) and telomeric (Tel) motif structures, we demonstrated that the Cen-B motif was largely responsible for this effect (p = 0.001). When the cause of NRM was investigated further, infection was the dominant cause of death (p = 0.006). No evidence correlating donor KIR B haplotype with relapse risk was observed. The results from this analysis confirm previous findings in the unrelated, TCD, MAC transplant setting and imply a protective role for donor-encoded Cen-A motifs against infection in allogeneic HCT recipients.

Original languageEnglish (US)
Pages (from-to)1975-1984
Number of pages10
JournalBone marrow transplantation
Volume55
Issue number10
DOIs
StatePublished - Oct 1 2020

Bibliographical note

Publisher Copyright:
© 2020, The Author(s), under exclusive licence to Springer Nature Limited.

Fingerprint

Dive into the research topics of 'Presence of donor-encoded centromeric KIR B content increases the risk of infectious mortality in recipients of myeloablative, T-cell deplete, HLA-matched HCT to treat AML'. Together they form a unique fingerprint.

Cite this